Atara Biotherapeutics Surges on FDA Leadership Shift, EBVALLO Review in Focus
Atara Biotherapeutics shares surged 18% Monday following news of an upcoming FDA leadership change, reviving investor hope for a reconsideration of its rejected EBVALLO therapy for a rare blood cancer.
Regulation
